Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 06, 2026, titled "Press Release - CuraTeQ Biologics Announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11".
Press Release Apr 06 2026
Filed with NSE · · 3 pages · English
Release
Earlier from Aurobindo Pharma
- Press Release Mar 04 2026
- Press Release Feb 26 2026
- Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
- Press Release Feb 13 2026
- Press Release Feb 09 2026
Later from Aurobindo Pharma
- Press Release Apr 07 2026
- Press Release Apr 17 2026
- Press Release May 21 2026
- Press Release Jun 03 2026
- Press Release Jun 04 2026
Follow Aurobindo Pharma into a list and get an email when it puts out news.
Follow Aurobindo Pharma